InSpace Experience Fragment
InSpace Experience Fragment

Elevating motion

InSpace is the industry’s only minimally invasive biodegradable, subacromial spacer for arthroscopic treatment of massive, irreparable rotator cuff tears (MIRCTs)*. It is designed to restore the subacromial space without requiring sutures or fixation devices.
 
InSpace presents a streamlined, arthroscopic procedural option that may result in sustained, clinically meaningful improvements in shoulder function and symptoms for your patients. (NCT02493660)



The solution you’ve been waiting for. The InSpace implant helps fill an unmet clinical need, arming you with a solution for MIRCTs that requires a shorter procedural time and is less invasive than other surgical treatment options.

See the efficiency

Clinically proven results

 

  • InSpace is the only FDA cleared MIRCT surgical solution supported by a level 1 randomized controlled trial that preserves musculoskeletal tissues and bone and does not require the use of anchor or permanent implant placement*.
  • Clinical trial evidence demonstrating clinically meaningful improvements in shoulder function and symptoms at two years.
    • High rate of clinical success, defined as meeting the study primary endpoint, in the InSpace study group at 24 months. (InSpace: 87.8%, Partial Repair: 88.1%)
Table 1: Primary composite endpoint - month 24

 

 

 

 

 

 

  • Early return to range of motion that is maintained out to 24 months.
  • InSpace resulted in a significant advantage for operative time compared to partial repair. (InSpace: 44 min, Partial Repair: 71 min)
  • Similar rates of Subsequent Secondary Surgical intervention (SSSI) through 24 months (InSpace: 4; Partial Repair 3). 
  • No InSpace devices required explanation.
  • No subject experienced a Serious Adverse Device Effect (SADE) through the entire 24 months of study.

 

*The InSpace™ subacromial tissue spacer system is indicated for the treatment of patients with massive, irreparable full-thickness torn rotator cuff tendons due to trauma or degradation with mild to moderate gleno-humeral osteoarthritis in patients greater than or equal to 65 years of age whose clinical conditions would benefit from treatment with a shorter surgical time compared to partial rotator cuff repair.